Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
News Medical on MSN2d
Study reveals immune system changes linked to schizophrenia and treatment resistanceResearchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, ...
Hosted on MSN2d
What Is the Difference Between Psychosis and Schizophrenia?Medically reviewed by Dakari Quimby, PhD Psychosis and schizophrenia are related but distinct mental health conditions ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...
Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback